Abstract
Summary
Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesity. A study published in 2024 reported on the experiences of people taking semaglutide. People living with obesity who took semaglutide had improvements in their physical, emotional, and social health. Sharing the experiences of people taking weight loss medications may help others make important treatment decisions.
Semaglutide is an approved medication for weight loss. In a recent study, people who lost weight while taking semaglutide had improved physical, mental, and social health.
The goal of this summary is to share the study results in accessible language so that people living with obesity can make informed decisions about whether a medication for weight loss is right for them.
Footnotes
Acknowledgements
The authors thank Taylor Tibbs, Sara Musetti-Jenkins, and Kate Lothman of RTI Health Solutions, a subsidiary of RTI International, for medical writing assistance.
Ethical Considerations
The STEP 1 protocol was approved by an independent ethics committee or institutional review board at each study site. All participants provided written informed consent.
Funding
Novo Nordisk A/S provided the financial support for the study. RTI Health Solutions, a subsidiary of RTI International, a nonprofit organization that conducts work for government, public, and private organizations, including pharmaceutical companies, received funding from Novo Nordisk A/S to provide publication support in the form of manuscript writing, styling, and submission.
Declaration of Conflicting Interests
RLK is a consultant for and shareholder of Novo Nordisk and receives royalties from Duke University for the IWQOL-Lite-CT. RK, HB, and JHHP are employees of Novo Nordisk A/S and may hold shares and/or stock options in the company.